SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 334 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $16,102,738 | -61.4% | 101,916 | -76.4% | 0.02% | -64.4% |
Q4 2023 | $41,691,498 | -20.2% | 432,350 | +0.3% | 0.04% | -27.4% |
Q3 2023 | $52,242,668 | -24.5% | 430,974 | -28.7% | 0.06% | -21.5% |
Q2 2023 | $69,208,541 | -27.2% | 604,336 | -12.4% | 0.08% | -28.2% |
Q1 2023 | $95,049,178 | +3.6% | 689,612 | -2.6% | 0.11% | +0.9% |
Q4 2022 | $91,731,455 | -9.5% | 707,946 | -22.8% | 0.11% | -16.8% |
Q3 2022 | $101,391,000 | +95.9% | 917,242 | +32.9% | 0.13% | +104.7% |
Q2 2022 | $51,744,000 | -23.0% | 690,295 | -19.7% | 0.06% | -7.2% |
Q1 2022 | $67,164,000 | -17.0% | 859,748 | -4.4% | 0.07% | -12.7% |
Q4 2021 | $80,960,000 | -5.8% | 899,056 | -3.2% | 0.08% | -14.1% |
Q3 2021 | $85,933,000 | +26.7% | 929,208 | +6.5% | 0.09% | +26.0% |
Q2 2021 | $67,829,000 | +2.7% | 872,292 | -1.5% | 0.07% | -8.8% |
Q1 2021 | $66,024,000 | -27.8% | 885,871 | +65.1% | 0.08% | -33.9% |
Q4 2020 | $91,454,000 | +10.9% | 536,417 | -8.6% | 0.12% | -8.3% |
Q3 2020 | $82,456,000 | -23.1% | 587,166 | -12.2% | 0.13% | -29.0% |
Q2 2020 | $107,273,000 | +106.8% | 669,036 | +26.1% | 0.19% | +57.6% |
Q1 2020 | $51,882,000 | -32.9% | 530,378 | -11.5% | 0.12% | -10.6% |
Q4 2019 | $77,291,000 | +53.3% | 598,968 | -10.5% | 0.13% | +38.9% |
Q3 2019 | $50,413,000 | -62.0% | 669,320 | -23.4% | 0.10% | -62.0% |
Q2 2019 | $132,783,000 | +1032.1% | 873,861 | +788.0% | 0.25% | +987.0% |
Q1 2019 | $11,729,000 | -71.4% | 98,403 | -73.8% | 0.02% | -76.3% |
Q4 2018 | $40,990,000 | +6.9% | 375,605 | +58.2% | 0.10% | +36.6% |
Q3 2018 | $38,340,000 | +356.0% | 237,387 | +273.2% | 0.07% | +317.6% |
Q2 2018 | $8,407,000 | +118.5% | 63,605 | +22.5% | 0.02% | +88.9% |
Q1 2018 | $3,848,000 | +61.3% | 51,937 | +21.1% | 0.01% | +50.0% |
Q4 2017 | $2,385,000 | -8.8% | 42,870 | -25.7% | 0.01% | -14.3% |
Q3 2017 | $2,616,000 | +149.6% | 57,668 | +85.5% | 0.01% | +133.3% |
Q2 2017 | $1,048,000 | +99.2% | 31,094 | +74.9% | 0.00% | +200.0% |
Q1 2017 | $526,000 | -32.6% | 17,778 | -37.5% | 0.00% | -50.0% |
Q4 2016 | $780,000 | – | 28,451 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Asymmetry Capital Management, L.P. | 87,180 | $2,581,000 | 3.60% |
Perceptive Advisors | 1,771,029 | $52,422,000 | 2.99% |
SPHERA FUNDS MANAGEMENT LTD. | 483,047 | $14,298,000 | 2.80% |
HealthCor Management, L.P. | 1,550,000 | $45,880,000 | 2.10% |
Camber Capital Management LP | 1,350,000 | $39,960,000 | 1.62% |
Tourbillon Capital Partners, L.P. | 1,537,518 | $45,511,000 | 1.17% |
Elk Creek Partners, LLC | 562,522 | $16,651,000 | 1.02% |
EMERALD ADVISERS, LLC | 818,705 | $24,234,000 | 1.00% |
EMERALD MUTUAL FUND ADVISERS TRUST | 604,467 | $17,892,000 | 0.82% |
Carlson Capital, L.P. | 1,845,702 | $54,633,000 | 0.70% |